GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Bloomage BioTechnology Corp Ltd (SHSE:688363) » Definitions » Capex-to-Revenue

Bloomage BioTechnology (SHSE:688363) Capex-to-Revenue : 0.09 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Bloomage BioTechnology Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Bloomage BioTechnology's Capital Expenditure for the three months ended in Dec. 2024 was ¥-137.12 Mil. Its Revenue for the three months ended in Dec. 2024 was ¥1,496.03 Mil.

Hence, Bloomage BioTechnology's Capex-to-Revenue for the three months ended in Dec. 2024 was 0.09.


Bloomage BioTechnology Capex-to-Revenue Historical Data

The historical data trend for Bloomage BioTechnology's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bloomage BioTechnology Capex-to-Revenue Chart

Bloomage BioTechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only 0.29 0.16 0.11 0.17 0.13

Bloomage BioTechnology Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.17 0.16 0.12 0.09

Competitive Comparison of Bloomage BioTechnology's Capex-to-Revenue

For the Specialty Chemicals subindustry, Bloomage BioTechnology's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bloomage BioTechnology's Capex-to-Revenue Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Bloomage BioTechnology's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bloomage BioTechnology's Capex-to-Revenue falls into.


;
;

Bloomage BioTechnology Capex-to-Revenue Calculation

Bloomage BioTechnology's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-721.388) / 5370.77
=0.13

Bloomage BioTechnology's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-137.122) / 1496.026
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bloomage BioTechnology  (SHSE:688363) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Bloomage BioTechnology Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bloomage BioTechnology's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Bloomage BioTechnology Business Description

Traded in Other Exchanges
N/A
Address
No. 678 Tianchen Avenue, High-Tech Development Zone, Shandong Province, Jinan City, CHN
Bloomage BioTechnology Corp Ltd manufactures and sells a variety of chemicals and chemical-based products, typically made from hyaluronic acid sodium, or HA. The firm organizes itself into two segments based on product type. The HA raw materials segment, which generates the majority of revenue, sells HA and HA derivatives produced using bio-fermentation technology. The HA raw materials segment products are classified into three grades of HA: medicine grade, cosmetic grade, and food grade. The HA end products segment sells medical skin care products, bone products for intra-articular injection, and medical beauty devices. The majority of revenue comes from China.
Executives
Zhao Yi Core technical personnel
Luan Yi Hong Core technical personnel
Shi Yan Li Core technical personnel
Liu Jian Jian Core technical personnel
Wang Yu Ling Core technical personnel
Zhou Wei Core technical personnel
Huang Si Ling Core technical personnel
Han Hong Ling Core technical personnel
Lu Zhen Core technical personnel

Bloomage BioTechnology Headlines

No Headlines